Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.61 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 3/20 | 0.58 |
| ▸ | CA2 | P00918 | 3/20 | 0.58 |
| ▸ | MME | P08473 | 6/20 | 0.57 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.56 |
| ▸ | ACE | P12821 | 6/20 | 0.56 |
| ▸ | CPA1 | P15085 | 1/20 | 0.56 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5490779 | 1.00 | FOLH1 (0.61) | FOLH1NAALAD2CA1CA2MME | |
| SCHEMBL5851226 | 1.00 | FOLH1 (0.61) | FOLH1NAALAD2CA1CA2MME | |
| Hydrochloric Acid SCHEMBL27515693 | 0.98 | FOLH1 (0.60) | FOLH1NAALAD2CA1CA2MME | |
| Hydrochloric Acid SCHEMBL6653534 | 0.98 | FOLH1 (0.60) | FOLH1NAALAD2CA1CA2MME | |
| SCHEMBL6377128 | 0.87 | FOLH1 (0.58) | FOLH1NAALAD2CA1CA2MME | |
| SCHEMBL5964935 | 0.87 | FOLH1 (0.58) | FOLH1NAALAD2CA1CA2MME | |
| SCHEMBL7275554 | 0.86 | CA2 (0.58) | FOLH1NAALAD2CA1CA2MME | |
| SCHEMBL20578232 | 0.86 | CA2 (0.58) | FOLH1NAALAD2CA1CA2MME | |
| SCHEMBL27167053 | 0.86 | CA2 (0.58) | FOLH1NAALAD2CA1CA2MME | |
| SCHEMBL1012022 | 0.86 | MME (0.63) | NAALAD2CA1CA2MMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7098020-B2 | DNA encoding hydantoinase, DNA encoding N-carbamyl-L-amino acid hydrolase, recombinant DNA, transformed cell, method of producing protein, and method of producing optically active amino acid | AJINOMOTO CO., INC. (JP) | 2006-08-29 | — | — | US | claimed |
| EP-1209234-A1 | STEREOSTRUCTURE OF DECARBAMYLASE AND METHOD OF USING THE SAME | Kaneka Corporation (JP) | 2002-05-29 | — | — | EP | claimed |
| EP-0159866-B1 | PROCESS FOR PRODUCTION OF L-AMINO ACIDS | DENKI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1991-04-03 | — | — | EP | claimed |
| EP-0159866-A2 | Process for production of L-amino acids | DENKI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1985-10-30 | — | — | EP | claimed |
| CN-115772513-B | D-carbamyl hydrolase mutant, gene, expression vector and application thereof | 江南大学 | 2025-05-02 | — | — | CN | disclosed |
| CN-109468304-B | Hydantoinase mutants | 赢创运营有限公司 | 2022-04-19 | — | — | CN | disclosed |
| US-10822627-B2 | Mutants of hydantoinase | EVONIK OPERATIONS GMBH (DE) | 2020-11-03 | — | — | US | disclosed |
| CN-109468304-A | The mutant of Hydantoinase | 赢创工业化学有限公司 | 2019-03-15 | — | — | CN | disclosed |
| US-20180237814-A1 | MUTANTS OF HYDANTOINASE | EVONIK TECHNOCHEMIE GMBH (DE) | 2018-08-23 | — | — | US | disclosed |
| US-20170266187-A1 | Pemetrexed Polymeric Nanoparticles And Methods Of Making And Using Same | PFIZER INC. (US) | 2017-09-21 | — | — | US | disclosed |
| US-8652528-B2 | Drug loaded polymeric nanoparticles and methods of making and using same | BIND THERAPEUTICS, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-20130251757-A1 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same | PFIZER INC. | 2013-09-26 | — | — | US | disclosed |
| EP-0925063-A4 | HYPOGLYCEMIC AND HYPOLIPIDEMIC COMPOUNDS | LILLY CO ELI (US) | 2000-12-27 | — | — | EP | disclosed |
| EP-0925063-A1 | HYPOGLYCEMIC AND HYPOLIPIDEMIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-06-30 | — | — | EP | disclosed |
| WO-1998000137-A1 | HYPOGLYCEMIC AND HYPOLIPIDEMIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1998-01-08 | — | — | WO | disclosed |
| EP-0801131-A1 | PROCESS FOR PRODUCING D-N-CARBAMOYL-$g(a)-AMINO ACID | Kanegafuchi Chemical Industry Co., Ltd. (JP) | 1997-10-15 | — | — | EP | disclosed |
| US-5412145-A | P2'-modified hydroxamic acid collagenase inhibitors | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1995-05-02 | — | — | US | disclosed |
| US-5300674-A | P2'-modified hydroxamic acid collagenase inhibitors | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1994-04-05 | — | — | US | disclosed |
| EP-0159866-B1 | PROCESS FOR PRODUCTION OF L-AMINO ACIDS | DENKI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1991-04-03 | — | — | EP | disclosed |
| EP-0159866-A2 | Process for production of L-amino acids | DENKI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1985-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130251757-A1 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same | LDHA, LDHB, LPXN | FOLH1 177/4885NAALAD2 2442/4885CA1 239/4885 |
| US-20170266187-A1 | Pemetrexed Polymeric Nanoparticles And Methods Of Making And Using Same | MTHFD1, TYMP, FPGS | FOLH1 51/4885NAALAD2 3323/4885CA1 2306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.